Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $46.93, representing a -1.59% change from its previous close.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.69, representing a -4.79% change from its previous close.
From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here
CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics AG NASDAQ: CRSP stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.
Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with modeled 2030 peak sales of $5.8B and orphan exclusivity until 2031. DCF-based fair value is $91.95, implying 73% upside with 57% revenue CAGR 2026-2035, but more conservative scenarios suggest CRSP might be fairly valued.
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027
CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient CRSP investors, with major upside expected as revenue scales and normalized EPS turns positive, likely post-2027. The 60/40 global profit split with Vertex offers operating leverage, positioning CRSP for free cash flow as adoption and execution improve.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.
